Half Year 2023 Vivoryon Therapeutics NV Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Christian Ehmann - Warburg Research GmbH - Analyst : Let's say, I was hoping -- I have 2 questions. So first one, would -- I was hoping that you could give us some more details about the potential scope of the VIVA-MIND update in Q4. So what kind of data we can expect in more detail a little bit. And the second question is a more broader one, but I've noticed when I looked at the FDA minutes from the approvals of Lecanemab and so on, that the FDA is quite -- has quite good propensity on using plaque reduction as a surrogate marker for potential cognition improvement. When I look at your, let's say, secondary endpoints, I see an MRI scan, but I see -- I don't see any PET scans. So maybe you can correct me on this, but I think you don't actually look exactly at the amount of REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 07, 2023 / 1:00PM, VVY.AS - Half Year 2023 Vivoryon Therapeutics NV Earnings Call plaque reduction. And if this is true, what do you think are your chances to getting a potential partner for varoglutamstat in the second -- in the first half of next year and so on, if the results are obviously positive, given that this might trigger some pushback from the FDA?

Question: Christian Ehmann - Warburg Research GmbH - Analyst : Yes. I misspoke and mix...

Question: Christian Ehmann - Warburg Research GmbH - Analyst : yes.